Physician profile
Nadiesda Costa
NPI 1457335895
$4,165.90
in general payments reported to CMS, 2019-2025
12 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $138 · 2022: $142 · 2023: $239 · 2024: $3,114 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $809 · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $809.04 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,500.00 | 2024 | |
| One Lambda, INC. | $450.00 | 2024 | |
| Eurofins Viracor, LLC | $168.05 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $152.58 | 2022-2025 | Envarsus |
| Travere Therapeutics, INC. | $147.08 | 2025 | |
| Vifor Pharma, INC. | $144.53 | 2023 | |
| Merck Sharp & Dohme LLC | $139.31 | 2024-2025 | Prevymis |
| Astrazeneca Pharmaceuticals LP | $126.35 | 2019 | |
| Akebia Therapeutics INC | $113.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.86 | 2023-2025 | Livtencity |
| Novo Nordisk INC | $73.67 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $59.09 | 2023-2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadiesda Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.